On March 21, the upgrade ceremony of Canton Biologics’ Foshan Kunlun commercial manufacturing base was successfully held at the Foshan Kehui Life Science and Technology Industrial Center. Leaders and guests from various functional bureaus of Foshan City, districts, and towns, as well as important partners of Canton Biologics, shareholder representatives, bankers, and media friends, attended the event to witness this milestone moment.

The successful holding of the upgrade ceremony marks a new phase for Canton Biologics, characterized by significantly increased production capacity and rapid market expansion. After in‑depth and continuous development, the Foshan Kunlun commercial base has achieved comprehensive upgrades in four core areas: commercial production capacity, technology platforms, information systems, and service scope. These upgrades will undoubtedly inject new vitality into the sustainable development of Canton Biologics and drive the company to new heights in the biotechnology field.

Grand Opening

The grand upgrade ceremony kicked off with a lively and vibrant lion dance. The colorful lions leaping into the air not only brought good fortune to the scene but also symbolized the thriving progress of Canton Biologics’ Foshan Kunlun commercial manufacturing base, soaring to new heights. The passionate lion dance performance filled the celebration with energy and enthusiasm.

Leadership Address

▲ Dr. Shen Xiao, Founder and CEO of Canton Biologics

At the beginning of the ceremony, Dr. Shen Xiao, Founder and CEO of Canton Biologics, delivered a speech. He stated that since its establishment in 2016, Canton Biologics has been committed to the mission of "Empowering the Future with Biotechnology," providing one‑stop services to global biopharmaceutical and biotechnology companies. After years of development, Canton Biologics has become a leader in the biotechnology field of the Guangdong‑Hong Kong‑Macao Greater Bay Area, establishing R&D, production, and clinical supply bases in Guangzhou, Foshan, Shanghai, and Berlin, Germany. Operating with an international perspective, the company provides professional and efficient services to global partners.

Recently, the Foshan Kunlun commercial base has undergone a series of upgrades. These upgrades have not only greatly improved the base’s production efficiency and capacity but also achieved a qualitative leap in service diversity.

In terms of commercial production capacity, comprehensive improvements in production and testing capabilities ensure that commercial capacity demands are met. In terms of technology platforms, the base’s renewal has injected new vitality into the R&D and innovation of new products, providing solid support for the company’s continuous innovation in biotechnology. The upgrade of the information system has not only made the base’s operations management more transparent and efficient but also enhanced the company’s decision‑making capabilities, ensuring the safety and efficiency of material storage. At the same time, the expansion of service scope enables the company to better meet the diverse needs of the market, further enhancing its competitiveness.

In addition, Canton Biologics will continue to expand its warehousing capacity and introduce electronic data management to make warehouse management intelligent and refined. The formulation workshop will upgrade its production lines to cover more dosage form filling types to meet evolving business needs.

▲ Wang Xu, General Manager of Xiamen Wantai Canghai

As an important strategic partner of Canton Biologics, Wang Xu, General Manager of Xiamen Wantai Canghai, delivered a speech. He stated that Canton Biologics is not only a partner of Xiamen Wantai Canghai but also an indispensable part of CMC development. In past collaborations, Canton Biologics has consistently delivered beyond expectations while ensuring rapid and efficient project execution, maximizing benefits in the shortest possible time. They have demonstrated strong professionalism and a high sense of responsibility. Looking ahead, he looks forward to continuing the partnership with Canton Biologics to jointly explore new models of clinical drug CMC services, develop more innovative drugs, and contribute to the health and well‑being of all humanity.

▲ Zhu Xixiong, Deputy Director of the Management Committee of Foshan Sanlongwan Science and Technology City

Subsequently, Zhu Xixiong, Deputy Director of the Management Committee of Foshan Sanlongwan Science and Technology City, delivered a speech. He stated that as an advanced manufacturing base and economically developed region in China, Foshan City has a solid industrial foundation in bioenergy, food, animal husbandry, bio‑based materials, medicine, and green cosmetic raw material production. Laying out cutting‑edge technologies and achieving transformation and implementation is essential for Foshan’s high‑quality development. As an excellent high‑tech enterprise, Canton Biologics has been thriving in recent years and has played a crucial role in the economic development of Foshan City, the promotion of innovative technologies, and the gathering of talent. In the future, the Foshan municipal government looks forward to joining hands with more excellent enterprises like Canton Biologics to jointly promote technological innovation, drive economic development, and improve people’s livelihoods.

Upgrade Ceremony

▲ Group photo of leaders at the "Renewal" upgrade ceremony

Amid great anticipation, accompanied by a grand salute of cannon fire and warm applause, the upgrade ceremony officially began. The "Renewal" upgrade ceremony not only sounded the clarion call for the comprehensive upgrade of Canton Biologics' technical services but also signified that the company has embarked on a new journey.

Site Tour

Guided by Canton Biologics staff, the guests divided into two groups and toured the facilities of the Foshan base, learning in detail about the various areas of the site.

On the fifth floor, in the QC laboratory, Canton Biologics staff provided a detailed introduction to the overall laboratory structure, the testing items available, the main functions and equipment of the microbiology laboratory, biochemistry laboratory, and physicochemical laboratory, as well as sample management, documentation, and COA management. Through the site visit, guests gained a deeper understanding of the laboratory’s research directions and specific environment.

On the sixth floor, using a screen display, Canton Biologics staff presented an illustrated explanation of the overall structure of the commercial production workshop, including the functional rooms and main equipment of the first‑floor drug substance workshop and the third‑floor drug product workshop. Through the meticulous introduction, the visiting guests learned about the production lines, scales, and process flows. Everyone expressed that they had gained a deeper understanding and appreciation of Canton Biologics.

Conclusion

Thus, the upgrade ceremony of Canton Biologics’ Foshan Kunlun commercial manufacturing base came to a successful conclusion. In the future, Canton Biologics will remain rooted in China, look to the world, serve the biopharmaceutical industry chain, help clients accelerate the journey from molecule to commercial production and market launch, and contribute to the development of the global biopharmaceutical industry.